Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin degludec/liraglutide vs insulin degludec or liraglutide in Chinese adults with type 2 diabetes on oral agents
CTR20170004Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started May 2017; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20170004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170004.